Our approach to advancing your therapies beyond milestones to transforming lives.
Catalyst is a niche provider of clinical research
services through two established solutions.
Premier provider of multi-therapeutic
resourcing and CRO services helping to
drive healthcare innovations to patients in need.
A biotech-focused, niche oncology CRO
helping to bring next-generation therapies
to cancer patients in need.
Your success is based on finding real solutions and getting real results.
You deserve a partner who is fully invested in giving you their undivided attention.
Building a culture of customer through collaboration and doing what’s right.
Latest News
Catalyst Marketing Director Emma Primon Honored with 40 Under 40 Leadership Award
Triangle Business Journal’s Annual Recognition Salutes Young Business and Community Leaders Raleigh, N.C., 1 June 2022 – Emma Primon, director of marketing and communications for Catalyst Clinical Research, has been named a recipient of the 40 Under 40 Leadership...
Catalyst Clinical Research Earns Recognition from Inc. Magazine as one of its Best Places to Work for 2022
This is the company's first year on Inc.’s coveted list and had the additional honor of being named in the Established Excellence: 5-14 years category for business. WILMINGTON, N.C., 10 May 2022 – Today, Catalyst Clinical Research, a market-leading provider of...
Catalyst Clinical Research Acquires Aptus Clinical to Accelerate European Expansion, Broaden Client Services, and Enhance Patient Impact
The transaction capitalizes on the two company’s combined geographic strengths, complementary service offerings and therapeutic expertise to advance industry-leading research for improved patient outcomes. WILMINGTON, N.C., ALDERLEY PARK, U.K, 4 May 2022 – Today,...
“What makes a difference in this industry is how organizations stand behind their work. Catalyst has been hugely successful because of their integrity and commitment to their customers. No matter how big or small the project, they are your partner and that is why I continue to work with them.”
Mid-size Biopharma
